Abstract:Age is the biggest risk factor for developing most forms of cancer. In breast cancer, over 50% of patients are over 60 years old; however, less than 25% of patients enrolled in clinical trials are in this age bracket. Furthermore, most mouse modeling is performed in young mice, meaning that from preclinical through clinical stages patients ages are not accurately reflected in trials designs. Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with no targeted therapies, so many treatment strategies utilize chemotherapy in combination with immunotherapy – which relies on a functional immune response. It is well known that immune function declines as we age, and thus therapeutic responses may differ with age. It is yet unclear how the tumor immune microenvironment changes with age, and how this may impact therapeutic response. Here, we utilize a mouse model which mimics hallmarks of human immune aging to understand how age impacts TNBC immune responses to dictate disease progression and therapeutic response. Immunologically young (8 weeks old) and aged (∼12 months old) FVB mice were orthotopically injected with syngeneic Met1 TNBC cells. Once tumors became palpable, mice were treated with paclitaxel chemotherapy or vehicle control and/or anti-PDL1 immunotherapy to mimic first-line therapeutic strategies. Tumors grew significantly faster in young control mice compared to aged, but young mice had a more robust response to therapy. Notable, only young mice had a significant benefit of combo therapy over monotherapy alone. Despite aged mice having more circulating CD8+ and CD4+ T cells, tumors in aged mice had significantly more infiltration of CD8+ cytotoxic T cells and FOXP3+ inhibitory T-regulatory cells compared to young control mice, yet only tumors in young mice exhibited an increase in T cell infiltration with therapy. Additionally, the ratio of CD8+ T cells and FOXP3+ Tregs was unchanged with age or treatment. Depletion of either CD8+ or CD4+ T cells led to a complete loss of age-associated differences in tumor growth. RNA sequencing analysis suggests that infiltrating T cells in aged mice may be exhausted due to a chronic interferon (IFN) phenotype, indicated by enrichment of IFN-alpha, IFN-gamma, and IL2 pathways, as well as increased expression of immune exhaustion markers PD1, CTLA4, TIM3 and LAG3. Neutralization of IFN-gamma blocks therapeutic response to anti-PDL1 in young mice but has no impact on aged mice. Analysis of published single cell RNAseq data indicated the same IFN response pathways enriched with age in human TNBC. These results demonstrate that the aging tumor immune microenvironment significantly impacts tumor progression and therapeutic response and suggest that targeting IFN signaling may lead to improved therapeutic responses. Together these findings establish a significant impact of immune aging on TNBC disease progression and response to therapy, highlighting the importance of developing age- stratified treatment strategies to improve responses in patients of all ages. Citation Format: Milos Spasic, Adrienne Parsons, Abigail Recko, Elizabeth Mittendorf, Peter van Galen, Sandra McAllister. Age dictates immune response within the tumor microenvironment of triple negative breast cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer; 2024 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(22_Suppl) nr C016.

Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy

Abstract 5513: Sexual differences in the aged melanoma tumor microenvironment dictates metastasis and therapeutic responses

Abstract PR003: Sex-dependent changes in the aged melanoma tumor microenvironment influence metastasis and therapeutic responses

Abstract 6107: Stromal and immune changes in the aged lung microenvironment create a permissive niche for the metastatic outgrowth of melanoma

Abstract 2688: Age-associated changes in macrophage function and phenotype affects cancer development, and the efficacy of macrophage targeted anticancer therapies in murine melanoma model

Sex differences in the aging murine urinary bladder and influence on the tumor immune microenvironment of a carcinogen-induced model of bladder cancer

Abstract 5537: How aging promotes immune mediated reactivation from metastatic melanoma dormancy

The influence of age and sex on the pre-treatment immune microenvironment of a carcinogen induced murine model of bladder cancer

Abstract 4282: Crosstalk between the immune system and the extracellular matrix in the context of melanoma and aging

Male melanoma comes of age

Senescence Reprogramming by MTHFD2 Deficiency Facilitates Tumor Progression

Abstract A003: The role of aging in promoting immune mediated reactivation from metastatic melanoma dormancy

Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women

Stromal changes in the aged lung induce an emergence from melanoma dormancy

Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response

Age-associated modulation of TREM1/2- expressing macrophages promotes melanoma progression and metastasis

Abstract C016: Age dictates immune response within the tumor microenvironment of triple negative breast cancer

Hematopoietic aging promotes cancer by fueling IL-1⍺-driven emergency myelopoiesis

Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility.

Abstract 5541: The unique metabolite landscape of the aged microenvironment dictates melanoma migratory and invasive capacity

Abstract 6592: Deciphering the effects of age on T cell immunity and immunotherapy